Cargando…

Current state and clinical outcome in Turkish patients with hepatocellular carcinoma

AIM: To investigate clinical, etiological, and prognostic features in patients with hepatocellular carcinoma. METHODS: Patients with hepatocellular carcinoma who were followed-up from 2001 to 2011 were included in the study. The diagnosis was established by histopathological and/or radiological crit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ekinci, Omer, Baran, Bulent, Ormeci, Asli Cifcibasi, Soyer, Ozlem Mutluay, Gokturk, Suut, Evirgen, Sami, Poyanli, Arzu, Gulluoglu, Mine, Akyuz, Filiz, Karaca, Cetin, Demir, Kadir, Besisik, Fatih, Kaymakoglu, Sabahattin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787684/
https://www.ncbi.nlm.nih.gov/pubmed/29399278
http://dx.doi.org/10.4254/wjh.v10.i1.51
_version_ 1783295982632435712
author Ekinci, Omer
Baran, Bulent
Ormeci, Asli Cifcibasi
Soyer, Ozlem Mutluay
Gokturk, Suut
Evirgen, Sami
Poyanli, Arzu
Gulluoglu, Mine
Akyuz, Filiz
Karaca, Cetin
Demir, Kadir
Besisik, Fatih
Kaymakoglu, Sabahattin
author_facet Ekinci, Omer
Baran, Bulent
Ormeci, Asli Cifcibasi
Soyer, Ozlem Mutluay
Gokturk, Suut
Evirgen, Sami
Poyanli, Arzu
Gulluoglu, Mine
Akyuz, Filiz
Karaca, Cetin
Demir, Kadir
Besisik, Fatih
Kaymakoglu, Sabahattin
author_sort Ekinci, Omer
collection PubMed
description AIM: To investigate clinical, etiological, and prognostic features in patients with hepatocellular carcinoma. METHODS: Patients with hepatocellular carcinoma who were followed-up from 2001 to 2011 were included in the study. The diagnosis was established by histopathological and/or radiological criteria. We retrospectively reviewed clinical and laboratory data, etiology of primary liver disease, imaging characteristics and treatments. Child-Pugh and Barcelona Clinic Liver Cancer stage was determined at initial diagnosis. Kaplan-Meier survival analysis was done to find out treatment effect on survival. Risk factors for vascular invasion and overall survival were investigated by multivariate Cox regression analyses. RESULTS: Five hundred and forty-five patients with hepatocellular carcinoma were included in the study. Viral hepatitis was prevalent and 68 patients either had normal liver or were non-cirrhotic. Overall median survival was 16 (13-19) mo. Presence of extrahepatic metastasis was associated with larger tumor size (OR = 3.19, 95%CI: 1.14-10.6). Independent predictor variables of vascular invasion were AFP (OR = 2.95, 95%CI: 1.38-6.31), total tumor diameter (OR = 3.14, 95%CI: 1.01-9.77), and hepatitis B infection (OR = 5.37, 95%CI: 1.23-23.39). Liver functional reserve, tumor size/extension, AFP level and primary treatment modality were independent predictors of overall survival. Transarterial chemoembolization (HR = 0.38, 95%CI: 0.28-0.51) and radioembolization (HR = 0.36, 95%CI: 0.18-0.74) provided a comparable survival benefit in the real life setting. Surgical treatments as resection and transplantation were found to be associated with the best survival compared with loco-regional treatments (log-rank, P < 0.001). CONCLUSION: Baseline liver function, oncologic features including AFP level and primary treatment modality determines overall survival in patients with hepatocellular carcinoma.
format Online
Article
Text
id pubmed-5787684
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-57876842018-02-02 Current state and clinical outcome in Turkish patients with hepatocellular carcinoma Ekinci, Omer Baran, Bulent Ormeci, Asli Cifcibasi Soyer, Ozlem Mutluay Gokturk, Suut Evirgen, Sami Poyanli, Arzu Gulluoglu, Mine Akyuz, Filiz Karaca, Cetin Demir, Kadir Besisik, Fatih Kaymakoglu, Sabahattin World J Hepatol Retrospective Cohort Study AIM: To investigate clinical, etiological, and prognostic features in patients with hepatocellular carcinoma. METHODS: Patients with hepatocellular carcinoma who were followed-up from 2001 to 2011 were included in the study. The diagnosis was established by histopathological and/or radiological criteria. We retrospectively reviewed clinical and laboratory data, etiology of primary liver disease, imaging characteristics and treatments. Child-Pugh and Barcelona Clinic Liver Cancer stage was determined at initial diagnosis. Kaplan-Meier survival analysis was done to find out treatment effect on survival. Risk factors for vascular invasion and overall survival were investigated by multivariate Cox regression analyses. RESULTS: Five hundred and forty-five patients with hepatocellular carcinoma were included in the study. Viral hepatitis was prevalent and 68 patients either had normal liver or were non-cirrhotic. Overall median survival was 16 (13-19) mo. Presence of extrahepatic metastasis was associated with larger tumor size (OR = 3.19, 95%CI: 1.14-10.6). Independent predictor variables of vascular invasion were AFP (OR = 2.95, 95%CI: 1.38-6.31), total tumor diameter (OR = 3.14, 95%CI: 1.01-9.77), and hepatitis B infection (OR = 5.37, 95%CI: 1.23-23.39). Liver functional reserve, tumor size/extension, AFP level and primary treatment modality were independent predictors of overall survival. Transarterial chemoembolization (HR = 0.38, 95%CI: 0.28-0.51) and radioembolization (HR = 0.36, 95%CI: 0.18-0.74) provided a comparable survival benefit in the real life setting. Surgical treatments as resection and transplantation were found to be associated with the best survival compared with loco-regional treatments (log-rank, P < 0.001). CONCLUSION: Baseline liver function, oncologic features including AFP level and primary treatment modality determines overall survival in patients with hepatocellular carcinoma. Baishideng Publishing Group Inc 2018-01-27 2018-01-27 /pmc/articles/PMC5787684/ /pubmed/29399278 http://dx.doi.org/10.4254/wjh.v10.i1.51 Text en ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Cohort Study
Ekinci, Omer
Baran, Bulent
Ormeci, Asli Cifcibasi
Soyer, Ozlem Mutluay
Gokturk, Suut
Evirgen, Sami
Poyanli, Arzu
Gulluoglu, Mine
Akyuz, Filiz
Karaca, Cetin
Demir, Kadir
Besisik, Fatih
Kaymakoglu, Sabahattin
Current state and clinical outcome in Turkish patients with hepatocellular carcinoma
title Current state and clinical outcome in Turkish patients with hepatocellular carcinoma
title_full Current state and clinical outcome in Turkish patients with hepatocellular carcinoma
title_fullStr Current state and clinical outcome in Turkish patients with hepatocellular carcinoma
title_full_unstemmed Current state and clinical outcome in Turkish patients with hepatocellular carcinoma
title_short Current state and clinical outcome in Turkish patients with hepatocellular carcinoma
title_sort current state and clinical outcome in turkish patients with hepatocellular carcinoma
topic Retrospective Cohort Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787684/
https://www.ncbi.nlm.nih.gov/pubmed/29399278
http://dx.doi.org/10.4254/wjh.v10.i1.51
work_keys_str_mv AT ekinciomer currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma
AT baranbulent currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma
AT ormeciaslicifcibasi currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma
AT soyerozlemmutluay currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma
AT gokturksuut currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma
AT evirgensami currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma
AT poyanliarzu currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma
AT gulluoglumine currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma
AT akyuzfiliz currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma
AT karacacetin currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma
AT demirkadir currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma
AT besisikfatih currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma
AT kaymakoglusabahattin currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma